LT 3001
Alternative Names: I-037; LT3001Latest Information Update: 16 Jun 2025
At a glance
- Originator Lumosa Therapeutics
- Developer Lumosa Therapeutics; Shanghai Pharmaceutical Group
- Class Antithrombotics; Neuroprotectants; Peptides; Small molecules; Vascular disorder therapies
- Mechanism of Action Antioxidants; Fibrinolytic agents; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Ischaemic stroke
Most Recent Events
- 23 Mar 2025 Lumosa Therapeutics completes the phase II BRIGHT trial in Ischaemic stroke in USA (IV, Infusion) (NCT05403866)
- 07 Feb 2024 Lumosa Therapeutics in collaboration with CHI Memorial initiates a phase IIb trial in Ischaemic stroke in USA
- 31 Dec 2023 Phase-II clinical trials in Ischaemic stroke (IV) (NCT05198323)